{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:26:35Z","timestamp":1761582395552,"version":"3.41.2"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to explore the efficacy of chidamide-containing regimens as maintenance therapy in patients with T- and natural killer (NK)-cell lymphomas (TNKLs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 51 patients with TNKLs who received chidamide-containing regimens after induction therapy were enrolled. The primary end point was progression-free survival (PFS), while the secondary end point was overall survival (OS) and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median duration of maintenance was 14 months (range = 1\u201324 months). Most of the patients were diagnosed with extranodal NK\/T-cell lymphoma (ENKTCL; 24\/51, 47.1%), followed by angioimmunoblastic T-cell lymphoma (AITL; 14\/51, 27.5%). The median PFS and OS were 21 and 29 months, respectively. The 2-year PFS and OS among the overall population were 45.1% and 54.2%, respectively. Patients who experienced complete remission (CR) after induction therapy had favorable survival compared with non-CR patients (partial remission\/stable disease, PR\/SD). Patients who experienced CR after first-line induction treatment also had favorable survival, but similar significance was not observed in the salvage treatment group. Although 86.3% of the patients had chidamide-related adverse events (AEs), severe hematological AEs (grade \u22653) occurred in only 11 (21.6%) patients, indicating the safe toxicity profile of chidamide.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The prolonged survival indicated that chidamide-containing maintenance therapy is promising and well tolerated in patients with TNKLs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1507418","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T07:06:09Z","timestamp":1740985569000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Retrospective study of chidamide-containing regimens as maintenance therapy among T-\u00a0and NK-cell lymphoma patients"],"prefix":"10.3389","volume":"15","author":[{"given":"Tao","family":"Hai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanchun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kexin","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270","article-title":"International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2924","article-title":"Comparison of first-line treatments of peripheral T-cell lymphoma according to regimen: A systematic review and meta-analysis","volume":"39","author":"Kim","year":"2021","journal-title":"Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071650","article-title":"Anaplastic large cell lymphoma: molecular pathogenesis and treatment","volume":"14","author":"Zhang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.9807","article-title":"Comparison of allogeneic stem cell transplant and autologous stem cell transplant in refractory or relapsed peripheral T-cell lymphoma: A systematic review and meta-analysis","volume":"4","author":"Du","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216634178","article-title":"Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma","volume":"23","author":"Campbell","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"B9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China","volume":"10","author":"Shi","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2021.05.08","article-title":"Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma","volume":"33","author":"Gui","year":"2021","journal-title":"Chin J Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.875469","article-title":"Chidamide maintenance therapy following induction therapy in patients with peripheral T-cell lymphoma who are ineligible for autologous stem cell transplantation: case series from China","volume":"12","author":"Guo","year":"2022","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/ajh.24992","article-title":"Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL)","volume":"93","author":"Zhang","year":"2018","journal-title":"Am J Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1738-9","article-title":"DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center","volume":"92","author":"Mikesch","year":"2013","journal-title":"Ann Hematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13045-020-00892-4","article-title":"Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)","volume":"13","author":"Mamez","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0098","article-title":"FDA approval summary: brentuximab vedotin in first-line treatment of peripheral T-cell lymphoma","volume":"24","author":"Richardson","year":"2019","journal-title":"Oncologist"},{"key":"B18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41392-024-01825-0","article-title":"Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib\/II study","volume":"9","author":"Gao","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104420","article-title":"Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-\u03b3 response in NK-T cell lymphoma","volume":"87","author":"Wen","year":"2023","journal-title":"EBioMedicine"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1507418\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T07:06:11Z","timestamp":1740985571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1507418\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":19,"alternative-id":["10.3389\/fonc.2025.1507418"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1507418","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"article-number":"1507418"}}